Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 177Lu-RAYZ-6114, RAYZ-6114, [177Lu]RAYZ 6114 |
Target |
Action antagonists |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | Japan | 31 May 2023 | |
Prostatic Cancer | Preclinical | United States | - |